Bausch Health Companies Inc. insider trading
Every open-market purchase and sale by Bausch Health Companies Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
Does following Bausch Health Companies Inc.’s insiders pay?
From March 12, 2010 to November 28, 2025, 48 insiders reported 104 open-market purchases and 33 sales not made under a pre-set plan in Bausch Health Companies Inc. Twelve months after each purchase was reported, the shares were +4.3% against the S&P 500 on average (median +9.9%), over 103 purchases with a full year of prices; 60% beat the index. After sales, the shares moved +22.8% against the index over 12 months (a negative figure means selling was the right call). Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on December 2, 2010 into $4,425 by November 2, 2026, −5.0% a year. It held shares 83% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $56,150 (+11.5% a year), and held throughout $81,743 (+14.1%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Farmer Ronald Harold | Director | 12 | −31.2% (12) | 33% | 0 | — | October 22, 2015 |
| De Schutter Richard U | Director | 10 | +15.8% (10) | 70% | 0 | — | August 6, 2021 |
| Paulson John | Director | 7 | −4.9% (7) | 43% | 2 | +46.6% (2) | August 14, 2025 |
| Kornwasser Laizer | EVP, Company Group Chairman | 6 | +21.4% (6) | 67% | 0 | — | March 25, 2014 |
| Provencio Norma Ann | Director | 4 | +22.7% (4) | 75% | 2 | +10.4% (2) | September 11, 2013 |
| Schiller Howard Bradley | EVP and CFO | 6 | +19.6% (6) | 100% | 0 | — | November 8, 2012 |
| Stolz Brian M. | EVP, Administration and CHCO | 6 | +14.9% (6) | 67% | 0 | — | August 12, 2013 |
| Papa Joseph C | CHAIRMAN & CEO | 5 | −20.5% (5) | 20% | 0 | — | September 13, 2019 |
| Paul Laurence E | Director | 4 | +43.6% (4) | 100% | 0 | — | June 5, 2012 |
| Segal Lloyd Mitchell | Director | 4 | +40.2% (4) | 100% | 0 | — | June 18, 2013 |
| Stevenson Katharine Berghuis | Director | 4 | +12.3% (4) | 75% | 0 | — | December 3, 2014 |
| Valueact Capital Management, L.P. | Director | 2 | −4.7% (2) | 50% | 2 | −34.3% (2) | June 12, 2015 |
| Valueact Holdings, L.P. | Director | 4 | +14.6% (4) | 75% | 0 | — | March 16, 2017 |
| Chouinard Michel | COO, Biovail Labs.Intl SRL | 0 | — | — | 3 | +142.0% (3) | December 1, 2010 |
| De Silva Rajiv | Pres & COO, Specialty Pharm | 1 | −1.1% (1) | 0% | 2 | +62.6% (2) | November 9, 2012 |
| Herendeen Paul | EVP and CFO | 3 | +19.7% (3) | 67% | 0 | — | September 17, 2018 |
| Humphries William D. | President, Ortho-Dermatologics | 1 | −42.6% (1) | 0% | 2 | −5.0% (2) | December 8, 2020 |
| Pearson J. Michael | Chief Executive Officer | 2 | +9.4% (2) | 100% | 1 | −86.8% (1) | November 9, 2015 |
| Ross Thomas W. SR. | Director | 3 | +17.6% (3) | 67% | 0 | — | March 16, 2020 |
| Va Partners I, LLC | Director | 2 | +48.3% (2) | 100% | 1 | −2.9% (1) | June 7, 2012 |
| Ackermann Christina | EVP AND GENERAL COUNSEL | 1 | +43.8% (1) | 100% | 1 | −69.7% (1) | June 4, 2021 |
| Chai-Onn Robert Roswell | EVP, GC and Corp. Secretary | 2 | −7.6% (2) | 0% | 0 | — | August 23, 2013 |
| Durham Mark Andrew | SVP Human Resources | 0 | — | — | 2 | +36.1% (2) | May 13, 2011 |
| Mirovsky Pavel | EVP, Pres. & GM Valeant EMENA | 0 | — | — | 2 | −8.2% (2) | June 3, 2015 |
| Rosiello Robert L. | EVP, Chief Financial Officer | 2 | −94.1% (2) | 0% | 0 | — | August 3, 2015 |
| Valueact Holdings II, L.P. | Director | 1 | +33.1% (1) | 100% | 1 | +33.1% (1) | June 9, 2020 |
| Von Eschenbach Andrew C. | Director | 2 | −15.8% (2) | 50% | 0 | — | August 9, 2021 |
| Wells William Mcdowall | Director | 0 | — | — | 2 | +62.3% (2) | December 8, 2010 |
| Appio Thomas | Pres&Co-Head Bausch&Lomb/Int'l | 1 | +21.6% (1) | 100% | 0 | — | December 18, 2018 |
| Eldessouky Sam | EVP & Chief Financial Officer | 0 | — | — | 1 | −64.8% (1) | June 15, 2021 |
| Fibiger Hans Christian | Chief Scientific Officer | 0 | — | — | 1 | +151.7% (1) | March 17, 2010 |
| Hall Susan | Global Head of R&D | 0 | — | — | 1 | +10.0% (1) | March 8, 2012 |
| Hassan Fred | Director | 1 | −5.8% (1) | 0% | 0 | — | September 3, 2013 |
| Ingram Robert Alexander | Director | 0 | — | — | 1 | +30.9% (1) | March 3, 2011 |
| Karabelas Argeris N | Director | 1 | −62.5% (1) | 0% | 0 | — | August 12, 2016 |
| Lee Frank D. | Director | 0 | — | — | 1 | −31.4% (1) | August 22, 2025 |
| Loberg Philip Walden Jr | EVP, Interim CFO | 1 | −20.4% (1) | 0% | 0 | — | June 13, 2011 |
| Mayer Christine | SVP, BTA Pharmaceuticals, Inc. | 0 | — | — | 1 | +72.9% (1) | August 10, 2010 |
| Mckenna Mark C. | President, Salix | 0 | — | — | 1 | −44.3% (1) | August 21, 2019 |
| Miller Steven D | Director | 1 | −57.6% (1) | 0% | 0 | — | December 2, 2021 |
When several insiders traded Bausch Health Companies Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Bausch Health Companies Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 15 buying crowds with six months of prices, it averaged −4.1% against the index. After 2 selling crowds, −11.6%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| September 30, 2021 | 2 buying | −12.5% | −23.9% | −59.8% |
| June 30, 2021 | 3 selling | −5.8% | −17.0% | −60.9% |
| March 31, 2020 | 4 buying | −2.2% | −34.0% | +48.5% |
| September 30, 2019 | 2 buying | +26.0% | −16.9% | −46.1% |
| September 28, 2018 | 3 buying | −14.5% | −2.3% | −26.2% |
| March 29, 2018 | 3 buying | +43.4% | +46.1% | +46.7% |
| November 30, 2017 | 2 buying | −11.3% | +26.7% | +39.5% |
| March 31, 2017 | 3 buying | +53.8% | +22.3% | +29.3% |
| June 30, 2016 | 2 buying | +21.4% | −38.0% | −31.9% |
| September 30, 2015 | 2 buying | −50.7% | −93.4% | −100.4% |
| June 30, 2015 | 3 buying | −20.7% | −56.2% | −93.4% |
| December 31, 2014 | 4 buying | +37.8% | +57.9% | −30.2% |
← Back to Bausch Health Companies Inc. · Funds · Politicians